. 2013 Apr 23;8(4):e62333. doi: 10.1371/journal.pone.0062333

Table 3. Malignancy incidence in primary recipient mice in Exp 2 (Donor: CD45.1⁺; Recipient: CD45.2⁺).

Vector	# Transplanted	VCN	# Vector+hematologicalMalignancies	# Other death*	# tumor free at autopsy(7–8 months)
Mock	15		0	1	14
MFG	15	0.81±0.31	0	1	14
SFFV	19	1.81±1.23	0	2	17
EF1α	15	1.59±0.39	0	0	15

Table 3. Malignancy incidence in primary recipient mice in Exp 2 (Donor: CD45.1+; Recipient: CD45.2+).